Effect of bevacizumab combined with gemcitabine in the treatment of patients with third-line non-squamous NSCLC
LI Yaoji
ZHU He
SHEN Zhigang
Abstract：Objective To observe the impact of bevacizumab combined with gemcitabine on tumor markers and survival in patients with third-line non-squamous non-small cell lung cancer(NSCLC).Methods A prospective controlled study design was adopted.A total of 116 patients with non-squamous NSCLC treated at Jinlin Cancer Hospital from Septem-ber 2020 to November 2023 were enrolled in the study and divided into the conventional treatment group with 58 cases and the monoclonal antibody treatment group with 58 cases according to the stratified randomization grouping method.The con-ventional treatment group was treated with cisplatin combined with gemcitabine,while the monoclonal antibody treatment group was given bevacizumab combined with gemcitabine.The therapeutic effect,tumor markers(carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),neuron-specific enolase(NSE)),quality of life(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30(EORTC QLQ-C30)and its lung cancer-specific module(QLQ-LC13)),survival time and incidence of adverse reactions were observed and compared between the conventional treatment group and the monoclonal antibody treatment group.Results After treatment,the objective remission rate(ORR),disease control rate(DCR)and survival rate of the monoclonal antibody treatment group were 34.48%(20/58),86.21%(50/58)and 79.31%(46/58),respectively,higher than 17.24%(10/58),58.62%(34/58)and 50.00%(29/58)of the conventional treatment group,and there were significant differences(χ2=4.496,11.048,10.902,P=0.034,0.001,0.001).The levels of CEA,CYFRA21-1 and NSE of the monoclonal antibody treatment group and the conventional treatment group were lower after treatment than those before treatment.The post-treatment levels of the above indicators in the monoclonal antibody treatment group were(13.97±2.40)μg/L,(10.55±1.17)ng/mL and(12.69±2.24)ng/mL,respectively,lower than(12.19±2.36)μg/L,(9.92±1.08)ng/mL and(11.36±3.05)ng/mL in the conventional treatment group,and there were significant differences(t=4.027,3.013,2.677,P<0.001,P=0.003,P=0.009).The scores of QLQ-C30 function and overall health of the monoclonal antibody treatment group and the conven-tional treatment group were higher after treatment than those before treatment,while the scores of QLQ-C30 symptom and QLQ-LC13 were lower.The scores of QLQ-C30 function and overall health of the monoclonal antibody treatment group were(65.25±8.73)and(67.81±6.57)points,respectively,higher than(61.67±8.10)and(64.13±6.26)points of the control group,and the scores of QLQ-C30 symptom and QLQ-LC13 of the monoclonal antibody treatment group were(29.81±5.20)and(29.11±3.07)points,respectively,lower than(33.18±5.53)and(32.56±3.12)points of the control group,with significant differences(t=2.289,3.008,3.381,6.003,P=0.024,0.003,0.001,<0.001).There was no significant difference in the incidence of adverse reactions between the monoclonal antibody treatment group and the conventional treatment group during treatment(P>0.05).Conclusion Bevacizumab combined with gemcitabine has significant efficacy in the treatment of third-line non-squamous NSCLC.This regimen helps inhibit tumor marker expression,improve quality of life,and prolong survival.Additionally,it exhibits a favorable safety profile.
Keywords：bevacizumabnon-squamous non-small cell lung cancersurvival prognosistumor markercombined treatmentgemcitabine
Publication Date：2026-03-25
Online Publishing Date：2026-04-07(First online date of this platform, not the publication date of the document)
Pages：5( 442-446 )